Pham Quang X sold $7K of CVKD
Pham Quang X (CEO and Chairman) sold 1,165 shares of Cadrenal Therapeutics, Inc. (CVKD) at $5.69 on 2026-05-22 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The market may interpret insider selling as caution, but 10b5-1 scheduling typically lowers the informational content versus unscheduled sales.
Market read
A disclosed insider open-market sale by a top executive can influence near-term sentiment, but no fundamental catalyst is provided.
What to watch
Consider whether other insiders/funds also sold around the same period, and whether CVKD has upcoming catalysts not mentioned here (e.g., trial/data, financing, partnerships).
Background
This is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
Cadrenal Therapeutics CEO/Chairman Pham Quang X sold 1,165 shares in an open-market transaction at $5.69 on a 10b5-1 plan.
Likely short-term sentiment drag or no material move; watch for follow-on insider activity and volume around the filing date.
The filing is a small, scheduled open-market sale (10b5-1) with no accompanying fundamental catalyst mentioned in the article.
Market effects
Limited sector read-through because this is a single-company insider transaction with no stated business development.
None indicated; transaction is company-specific.
None indicated; no international deal/regulatory event referenced.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than negative expectations.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider sale by its CEO/Chairman.
- insiderPham Quang X
CEO and Chairman; sold 1,165 shares at $5.69 under a 10b5-1 plan.
